FLT3 Gene Mutation Quantitative Monitoring Test in UAE | 650 AED | 2026 DHA Guidelines

تحليل رصد طفرة جين FLT3 الكمي في الإمارات | 650 درهم | إرشادات هيئة الصحة بدبي 2026

الملخص التنفيذي: فحص كمي متقدم لطفرة FLT3 باعتماد هيئة الصحة بدبي – دقة تشخيصية تصل إلى 99.9% لمراقبة ابيضاض الدم النقوي الحاد واتخاذ القرار العلاجي.

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) accredited processing.
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection & VIP Mobile Phlebotomy (8 AM - 11 PM).
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed physicians.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Clinical Test Overview & UAE Comparison

The FLT3 quantitative monitoring test precisely measures the variant allele frequency of FLT3-ITD and tyrosine kinase domain mutations in peripheral blood or bone marrow of leukemia patients, essential for assessing minimal residual disease and guiding tyrosine kinase inhibitor therapy. يقيس فحص FLT3 الكمي بدقة تردد الأليل الطافر في الدم أو نخاع العظم لمرضى ابيضاض الدم، وهو أساسي لتقييم المرض المتبقي وضبط العلاج بمثبطات التيروزين كيناز.

Feature	Our Test (DHA-Certified)	Closest Alternative
Methodology	Real-Time PCR (qPCR) with allelic discrimination, cross-validated by WGS	Sanger sequencing or single-gene PCR
Sensitivity	0.01% mutant allele in wild-type background (ISO-verified)	~1-5% (may miss low-level MRD)
Turnaround Time	Sample Mon/Thu by 11 AM – Report Wed/Sat	7-10 working days
Pre-test Requirement	MRD Requisition Form (Form 22) with historical data	Often missing dedicated MRD protocol

Physician Insight & Safety Protocol

“As a hematologist, I understand the anxiety that accompanies FLT3 monitoring. This quantitative assay is a vital tool, but it must always be interpreted within the full clinical picture—rise in mutation burden does not automatically mean treatment failure. Please continue your prescribed medication and consult your hematologist before any modification.” — Dr. PRABHAKAR REDDY, DHA License: 61713011.

Medication Warning: Do not discontinue or alter prescribed medication (especially FLT3 inhibitors) without consulting your treating physician.

Exclusion Criteria & Emergency Red Flags

Do not proceed with home collection if the patient has active high fever (>38.5°C), uncontrolled bleeding, or suspected tumor lysis syndrome – escalate to ER immediately.
Bone marrow aspirate is excluded in patients with uncorrected severe coagulopathy or infection at the aspiration site.
Minors require a legal guardian’s consent per Federal Law No. 3 of 2016 (Child Rights) and DHA policy.
If the patient experiences sudden bruising, petechiae, or shortness of breath after collection, seek emergency care.

Patient FAQ & Clinical Guidance

1. What is the FLT3 gene mutation quantitative monitoring test and why is it needed?

Snippet: The FLT3 quantitative mutation test measures the percentage of leukemic cells carrying FLT3-ITD or TKD mutations to assess minimal residual disease and guide targeted therapy decisions.

This highly sensitive assay detects and quantifies the abnormal gene copies in your blood or bone marrow, enabling your oncologist to track response to treatment and detect early relapse. The test is performed using Real-Time PCR, which can identify one mutated cell among 10,000 normal cells. Regular monitoring is crucial for acute myeloid leukemia patients receiving FLT3 inhibitors.

يقيس الاختبار نسبة الخلايا ابيضاض الدم الحاملة لطفرة FLT3 لتقييم المرض المتبقي وتوجيه العلاج بمثبطات FLT3. يساعد الطبيب في كشف الانتكاس المبكر بدقة عالية.

2. How does this test help in leukemia treatment monitoring?

Snippet: Serial quantitative monitoring of FLT3 mutation burden allows dynamic risk stratification and timely intervention, significantly improving progression-free survival in FLT3-mutated AML.

By comparing mutation levels before, during, and after therapy, hematologists can identify molecular remission or resistance. A rising FLT3 level may prompt a change in drug dosage or combination therapy, while a sustained negative result reassures continued response. The integrates with MRD (minimal residual disease) protocols, offering a non-invasive window into disease activity.

تتيح مراقبة حمل الطفرة بمرور الوقت تصنيف المخاطر الديناميكي وتحسين فرص البقاء دون تقدم المرض. يمكن للطبيب تعديل العلاج بناءً على تغيرات مستوى الطفرة.

3. What are the sample requirements and how quickly will I receive the result?

Snippet: A 5 mL whole blood or bone marrow sample in an EDTA lavender-top tube, shipped refrigerated and never frozen, is required; results are delivered by Saturday if collected by Thursday 11 AM.

A duly filled MRD Requisition Form (Form 22) with complete historical data is mandatory to process the specimen. Home phlebotomy or bone marrow collection is arranged by our DHA-licensed team. Samples are accepted only on Monday and Thursday before 11 AM, with corresponding reports on Wednesday and Saturday. Do not freeze the sample under any circumstances—refrigerated transport maintains sample integrity.

يجب جمع 5 مل من الدم أو نخاع العظم في أنبوب EDTA بنفسجي، ونقلها مبردة دون تجميد. تُسلم النتائج يوم السبت إذا تم السحب قبل 11 صباح الخميس مع استيفاء نموذج MRD.

UAE Federal Decree-Law No. 41 of 2024 (Art. 87) compliance ensured. Personal data handled per UAE PDPL. ISO 9001:2015 Certified (INT/EGQ/2509DA/3139). DHA Facility License: 9834453. Contact: +971 54 548 8731.

ICD-10-CM 2026: C92.62 (FLT3 gene mutation), Z51.81 (Encounter for therapeutic drug level monitoring), C92.00 (Acute myeloblastic leukemia, not having achieved remission). LOINC: 82291-1 (FLT3 gene targeted mutation analysis).

دعم ثنائي اللغة متاح